Some patients have tumor cells that do not express PD-L1 yet they still respond to treatment with anti-PD-1/PD-L1 inhibitors12, suggesting that immune:immune cell interactions may be a key responsive target of anti-PD-1/PD-L1 therapies12. This evidence concerns the gene CD274 and neoplasm.